An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Canagliflozin 50 mg
Placebo
Canagliflozin 150 mg
Metformin
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Canagliflozin, Placebo, Metformin, Hemoglobin A1c, Type 2 diabetes mellitus
Eligibility Criteria
Inclusion Criteria:
- All patients must have a diagnosis of T2DM and be currently treated with metformin
- Patients in the study must have a HbA1c between >=7 and <=10.5%
- Patients must have a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)
Exclusion Criteria:
- History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Canagliflozin 50 mg bid
Canagliflozin 150 mg bid
Placebo
Arm Description
Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
Each patient will receive matching placebo twice daily for 18 weeks
Outcomes
Primary Outcome Measures
Change in HbA1c From Baseline to Week 18
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
Secondary Outcome Measures
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 18
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
Percent Change in Body Weight From Baseline to Week 18
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.
Percentage of Patients With HbA1c <7% at Week 18
The table below shows the percentage of patients with HbA1c <7% at Week 18 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.
Full Information
NCT ID
NCT01340664
First Posted
April 21, 2011
Last Updated
September 5, 2014
Sponsor
Janssen Research & Development, LLC
1. Study Identification
Unique Protocol Identification Number
NCT01340664
Brief Title
An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Official Title
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
July 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Janssen Research & Development, LLC
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (ie, treatment with a single drug) and have inadequate glycemic (blood sugar) control.
Detailed Description
This is a randomized (study drug assigned by chance), double-blind (neither the patient nor the study doctor will know the identity of assigned study drug), placebo-controlled, parallel-group,3-arm (3 treatment groups) multicenter study to determine the efficacy, safety, and tolerability of canagliflozin compared to placebo (a capsule that is identical in appearance to canagliflozin but does not contain active drug) in patients with type 2 diabetes mellitus (T2DM) who are not achieving an adequate response from current antihyperglycemic therapy with metformin to control their diabetes. Canagliflozin (a Sodium-Glucose Cotransporter 2 inhibitor) is currently under development to lower blood sugar levels in patients with T2DM. Patients will take single-blind placebo capsules orally (by mouth) for 2 weeks before randomization. Patients will be randomly assigned canagliflozin or matching placebo, orally, twice daily, with 1 capsule taken with the morning meal and 1 capsule taken with the evening meal (2 capsules per day) and concurrent with metformin, if applicable, for up to 18 weeks. The dosing time of metformin should remain the same throughout the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Canagliflozin, Placebo, Metformin, Hemoglobin A1c, Type 2 diabetes mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
279 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Canagliflozin 50 mg bid
Arm Type
Experimental
Arm Description
Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
Arm Title
Canagliflozin 150 mg bid
Arm Type
Experimental
Arm Description
Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Each patient will receive matching placebo twice daily for 18 weeks
Intervention Type
Drug
Intervention Name(s)
Canagliflozin 50 mg
Intervention Description
One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
1 placebo capsule taken orally twice daily with a meal for 18 weeks
Intervention Type
Drug
Intervention Name(s)
Canagliflozin 150 mg
Intervention Description
1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
Primary Outcome Measure Information:
Title
Change in HbA1c From Baseline to Week 18
Description
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
Time Frame
Day 1 (Baseline) and Week 18
Secondary Outcome Measure Information:
Title
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 18
Description
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.
Time Frame
Day 1 (Baseline) and Week 18
Title
Percent Change in Body Weight From Baseline to Week 18
Description
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.
Time Frame
Day 1 (Baseline) and Week 18
Title
Percentage of Patients With HbA1c <7% at Week 18
Description
The table below shows the percentage of patients with HbA1c <7% at Week 18 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.
Time Frame
Week 18
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All patients must have a diagnosis of T2DM and be currently treated with metformin
Patients in the study must have a HbA1c between >=7 and <=10.5%
Patients must have a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)
Exclusion Criteria:
History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Janssen Research & Development, LLC Clinical Trial
Organizational Affiliation
Janssen Research & Development, LLC
Official's Role
Study Director
Facility Information:
City
Little Rock
State/Province
Arkansas
Country
United States
City
National City
State/Province
California
Country
United States
City
Spring Valley
State/Province
California
Country
United States
City
Bradenton
State/Province
Florida
Country
United States
City
Marianna
State/Province
Florida
Country
United States
City
Savannah
State/Province
Georgia
Country
United States
City
Avon
State/Province
Indiana
Country
United States
City
Valparaiso
State/Province
Indiana
Country
United States
City
Madisonville
State/Province
Kentucky
Country
United States
City
Metairie
State/Province
Louisiana
Country
United States
City
Charlotte
State/Province
North Carolina
Country
United States
City
Columbus
State/Province
Ohio
Country
United States
City
Mason
State/Province
Ohio
Country
United States
City
Perrysburg
State/Province
Ohio
Country
United States
City
Tulsa
State/Province
Oklahoma
Country
United States
City
Yukon
State/Province
Oklahoma
Country
United States
City
Oregon City
State/Province
Oregon
Country
United States
City
Pittsburg
State/Province
Pennsylvania
Country
United States
City
East Providence
State/Province
Rhode Island
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Pearland
State/Province
Texas
Country
United States
City
San Antonio
State/Province
Texas
Country
United States
City
Bountiful
State/Province
Utah
Country
United States
City
Virginia Beach
State/Province
Virginia
Country
United States
City
Milwaukee
State/Province
Wisconsin
Country
United States
City
St. John'S
State/Province
Newfoundland and Labrador
Country
Canada
City
Halifax
State/Province
Nova Scotia
Country
Canada
City
Brampton
State/Province
Ontario
Country
Canada
City
Toronto
State/Province
Ontario
Country
Canada
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
City
Beroun
Country
Czech Republic
City
Olomouc 9
Country
Czech Republic
City
Ostrava
Country
Czech Republic
City
Pardubice
Country
Czech Republic
City
Pisek
Country
Czech Republic
City
Prague 10
Country
Czech Republic
City
Praha 11
Country
Czech Republic
City
Znojmo
Country
Czech Republic
City
Aguascalientes
Country
Mexico
City
Guadalajara, Jalisco.
Country
Mexico
City
Monterrey
Country
Mexico
City
Tampico
Country
Mexico
City
Bacau
Country
Romania
City
Brasov
Country
Romania
City
Bucharest
Country
Romania
City
Cluj-Napoca
Country
Romania
City
Galati
Country
Romania
City
Targu Mures
Country
Romania
City
Kursk
Country
Russian Federation
City
Moscow
Country
Russian Federation
City
Saint-Petersburg
Country
Russian Federation
City
Samara
Country
Russian Federation
City
Saratov
Country
Russian Federation
City
St Petersburg
Country
Russian Federation
City
St-Petersburg
Country
Russian Federation
City
Tyumen
Country
Russian Federation
City
Voronezh
Country
Russian Federation
City
Banska Bystrica
Country
Slovakia
City
Bratislava
Country
Slovakia
City
Kosice
Country
Slovakia
City
Presov
Country
Slovakia
City
Sahy
Country
Slovakia
City
Trebisov
Country
Slovakia
12. IPD Sharing Statement
Citations:
PubMed Identifier
29159083
Citation
Qiu R, Capuano G, Meininger G. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. J Clin Transl Endocrinol. 2014 May 5;1(2):54-60. doi: 10.1016/j.jcte.2014.04.001. eCollection 2014 Jun.
Results Reference
derived
Learn more about this trial
An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
We'll reach out to this number within 24 hrs